Clinical trials: Advanced Non-small Cell Lung Cancer (NSCLC)
- Condition Advanced Non-small Cell Lung Cancer (NSCLC)
- Funder type Industry (pharma, biotech, devices)
Non Small Cell Lung Carcinoma
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
- Trial name
- NCT00080340
- Testing
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Where
- 338 sites in United States, Argentina and 6 more
- Volunteers
- 520 people
- Sponsor
- Telik
Lung Cancer
Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates
A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.
- Trial name
- NCT02845089
- Volunteers
- 382 people
- Sponsor
- Bristol-Myers Squibb
Advanced NSCLC, Metastatic Lung Cancer
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%…
- Trial name
- NCT05609578
- Testing
- Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed
- Where
- 94 sites in United States, France and 5 more
- Volunteers
- 90 people
- Sponsor
- Mirati Therapeutics Inc.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Advanced Tumors, Melanoma
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a…
- Conditions
- Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease
- Trial name
- NCT04198818
- Testing
- HH2710
- Where
- 3 sites in United States, China
- Volunteers
- 37 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Non-small Cell Lung Cancer
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study.
- Trial name
- EGFR (NCT05442060)
- Testing
- 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily)
- Where
- 7 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- OBI Pharma, Inc
Non-Small Cell Lung Cancer
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with…
- Trial name
- NCT01493843
- Testing
- pictilisib, bevacizumab, carboplatin
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 501 people
- Sponsor
- Genentech, Inc.
Advanced Non-Small Cell Lung Cancer
HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.
- Trial name
- NCT07105176
- Testing
- Cyclophosphamide, Fludarabine, IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.
NSCLC, NSCLC Stage IV
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic…
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer
- Trial name
- NCT05652868
- Testing
- MYTX-011
- Where
- 55 sites in United States, Australia and 5 more
- Volunteers
- 227 people
- Sponsor
- Mythic Therapeutics
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Advanced Non-small Cell Lung Cancer
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based…
- Trial name
- NCT02582125
- Testing
- ONO-4538
- Where
- 8 sites in Taiwan
- Volunteers
- 53 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.
- Trial name
- NCT05275868
- Testing
- MGY825
- Where
- 15 sites in United States, Germany and 4 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC)…
- Trial name
- Checkmate 171 (NCT02409368)
- Testing
- Nivolumab
- Where
- 90 sites in Austria, Denmark and 11 more
- Volunteers
- 812 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
- Trial name
- NCT06905197
- Testing
- DZD6008, Sunvozertinib
- Where
- 5 sites in United States, Australia
- Volunteers
- 140 people
- Sponsor
- Dizal Pharmaceuticals
Non-Small Cell Lung Cancer
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet…
- Trial name
- CheckMate 078 (NCT02613507)
- Testing
- Nivolumab, Docetaxel
- Where
- 33 sites in China, Hong Kong and 2 more
- Volunteers
- 504 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who…
- Trial name
- FIGHT-210 (NCT05253807)
- Testing
- Pemigatinib
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer, NSCLC
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a single-arm, open-label, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of rulonilimab combined with chemotherapy in patients with advanced or metastatic non-small cell lung Cancer (NSCLC).
- Conditions
- Non-small Cell Lung Cancer, NSCLC, PD-1
- Trial name
- NCT05741021
- Testing
- F520, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer, Breast Cancer
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic…
- Trial name
- NCT05653752
- Testing
- YL202
- Where
- 13 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Carcinoma, Non-Small-Cell Lung Cancer
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy…
- Trial name
- NCT03240393
- Testing
- INC280
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.